Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emicizumab in mild or moderate hemophilia A without FVIII inhibitors
2019-002179-32Phase 3Recruiting
- Sponsor
- Roche
- Start
- Sep 2019
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of emicizumab in hemophilia A, sponsored by Roche. Primary endpoint: Safety. Started Sep 2019; status: recruiting.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2019-002179-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002179-32.